Lokal İleri Meme Kanseri

Aebi S, Karlsson P, Wapnir IL. Locally advanced breast cancer. The Breast, 2022;62(Supplement 1):S58-S62. doi:10.1016/j.breast.2021.12.011

Mutebi M, Anderson BO, Duggan C, et al. Breast cancer treatment: A phased approach to implementation. Cancer, 2020;126(Supplement 10):2365-2378. doi:10.1002/cncr.32910

Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Frontiers in Pharmacology, 2021;11:632079. doi:10.3389/fphar.2020.632079

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., ... & O’Shaughnessy, J. (2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine, 382(9), 810-821.

Tolaney SM, Garrett-Mayer E, White J, et al. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. Journal of Clinical Oncology, 2021;39(24):2720-2731. doi:10.1200/JCO.20.03613

Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., ... & ESMO Guidelines Committee. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 30(8), 1194-1220.

Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., ... & Von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet, 384(9938), 164-172.

Schmid, P., Cortes, J., Dent, R., McArthur, H., Pusztai, L., Kümmel, S., ... & O’Shaughnessy, J. (2024). Overall survival with pembrolizumab in early-stage triple-negative breast cancer. New England Journal of Medicine, 391(21), 1981-1991.

Von Minckwitz, G., Huang, C. S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., ... & Geyer Jr, C. E. (2019). Trastuzumab emtansine for residual invasive HER2-positive breast cancer. New England Journal of Medicine, 380(7), 617-628.

Magbanua, M. J. M., Swigart, L. B., Wu, H. T., Hirst, G. L., Yau, C., Wolf, D. M., ... & van‘t Veer, L. J. (2021). Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Annals of Oncology, 32(2), 229-239.

Plichta JK, Ren Y, Thomas SM, et al. Implications for breast cancer restaging based on the 8th edition AJCC staging manual. Annals of Surgery, 2020;271(1):169-176. doi:10.1097/SLA.0000000000003071

Jagsi R, Mason G, Overmoyer BA, et al. Inflammatory breast cancer defined: Proposed common diagnostic criteria to guide treatment and research. Breast Cancer Research and Treatment, 2022;192(2):235-243. doi:10.1007/s10549-021-06434-x

Pusztai L. Systemic staging of locally advanced breast cancer: How hard to look? Journal of Clinical Oncology, 2023;41(23):3891-3894. doi:10.1200/JCO.23.00977

Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., ... & Kumar, R. (2023). Breast Cancer, Version 4.2023 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 21(6), 594-608.

Iramakani M, El Zawawy S, El Din Khalil D, et al. Value of dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of breast cancer. Egyptian Journal of Radiology and Nuclear Medicine, 2020;51:57. doi:10.1186/s43055-020-00178-9

Rubio, I. T., Marotti, L., Biganzoli, L., Aristei, C., Athanasiou, A., Campbell, C., ... & Curigliano, G. (2024). EUSOMA quality indicators for non-metastatic breast cancer: an update. European Journal of Cancer, 198, 113500.

Bick U, Trimboli RM, Athanasiou A, et al. Image-guided breast biopsy and localisation: Recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights into Imaging, 2020;11(1):12. doi:10.1186/s13244-019-0803-x

Di Paola, V., Mazzotta, G., Conti, M., Palma, S., Orsini, F., Mola, L., ... & Manfredi, R. (2023). Image-guided localization techniques for metastatic axillary lymph nodes in breast cancer; what radiologists should know. Cancers, 15(7), 2130.

Eisen A, Fletcher GG, Fienberg S, et al. Breast Magnetic Resonance Imaging for Preoperative Evaluation of Breast Cancer: A Systematic Review and Meta-Analysis. Can Assoc Radiol J. 2024;75(1):118-135. doi:10.1177/08465371231184769

Siso, C., de Torres, J., Esgueva-Colmenarejo, A., Espinosa-Bravo, M., Rus, N., Cordoba, O., ... & Rubio, I. T. (2018). Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA Trial) a new tool to guide the excision of the clipped node after neoadjuvant treatment. Annals of surgical oncology, 25(3), 784-791.

Hadebe B, Harry L, Ebrahim T, et al. The role of PET/CT in breast cancer. Diagnostics, 2023;13(4):597. doi:10.3390/diagnostics13040597

Kerr AJ, Dodwell D, McGale P, et al. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treatment Reviews, 2022;109:102375. doi:10.1016/j.ctrv.2022.102375

Masuda, N., Lee, S. J., Ohtani, S., Im, Y. H., Lee, E. S., Yokota, I., ... & Toi, M. (2017). Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine, 376(22), 2147-2159.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277-1292. doi:10.1016/S0140-6736(23)00285-4

Wang C, Chen J, Xu X, et al. Dual HER2 blockade in neoadjuvant treatment of HER2+ breast cancer: A meta-analysis and review. Technology in Cancer Research and Treatment, 2020;19:1533033820960726. doi:10.1177/1533033820960726

Cipolla G, Gebbia V, D’Agati E, et al. Comprehensive axillary management of clinically node-positive (cN+) breast cancer patients: A narrative review on neoadjuvant chemotherapy. Cancers, 2024;16(19):3354. doi:10.3390/cancers16193354

Cavalcante FP, Zerwes FP, Millen EC, et al. Oncoplastic surgery in the treatment of breast cancer: a review of evolution and surgical training. Chin Clin Oncol. 2025;14(2):20. doi:10.21037/cco-24-140

Qin S, Wang X, Chen P, et al. Survival outcomes of breast-conserving surgery versus mastectomy in locally advanced breast cancer following neoadjuvant chemotherapy: A meta-analysis. Technology in Cancer Research and Treatment, 2024;23:1-11. doi:10.1177/15330338241240127

Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., ... & Morrow, M. (2014). Society of Surgical Oncology–American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. International Journal of Radiation Oncology* Biology* Physics, 88(3), 553-564.

Clough, K. B., Kaufman, G. J., Nos, C., Buccimazza, I., & Sarfati, I. M. (2010). Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. Annals of surgical oncology, 17(5), 1375-1391.

Caudle, A. S., Yang, W. T., Krishnamurthy, S., Mittendorf, E. A., Black, D. M., Gilcrease, M. Z., ... & Kuerer, H. M. (2016). Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. Journal of Clinical Oncology, 34(10), 1072-1078.

Giuliano, A. E., Hunt, K. K., Ballman, K. V., Beitsch, P. D., Whitworth, P. W., Blumencranz, P. W., ... & Morrow, M. (2011). Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama, 305(6), 569-575.

Donker, M., Van Tienhoven, G., Straver, M. E., Meijnen, P., Van De Velde, C. J., Mansel, R. E., ... & Rutgers, E. J. (2014). Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. The lancet oncology, 15(12), 1303-1310.

Matar DY, Wu M, Haug V, et al. Surgical complications in immediate and delayed breast reconstruction: A systematic review and meta-analysis. Journal of Plastic, Reconstructive & Aesthetic Surgery, 2022;75(11):4085-4095. doi:10.1016/j.bjps.2022.08.029

Piccolo, P. P., Venturi, M., Mesbahi, A. N., & Nahabedian, M. Y. (2023). Current status prepectoral and subpectoral breast reconstruction in the USA. Gland Surgery, 12(12), 1794.

Belkacemi Y, Geara F, Albashiri M, et al. Breast reconstruction and post-mastectomy radiotherapy: Complications and quality of life considerations. Critical Reviews in Oncology/Hematology, 2024;199:104384. doi:10.1016/j.critrevonc.2024.104384

Eisen A, Somerfield MR, Accordino MK, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. Journal of Clinical Oncology, 2022;40(7):787-800. doi:10.1200/JCO.21.02647

Chen SY, Sun GY, Tang Y, et al. Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial. European Journal of Cancer, 2022;174:153-164. doi:10.1016/j.ejca.2022.07.007

Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., ... & Griggs, J. J. (2019). Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. Journal of Clinical Oncology, 37(5), 423-438.

Tolaney SM, Tarantino P, Graham N, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023;24(3):273-285. doi:10.1016/S1470-2045(23)00051-7

Johnston, S. R., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., ... & monarchE Committee Members and Investigators. (2020). Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). Journal of Clinical Oncology, 38(34), 3987-3998.

De Rose F, Meduri B, De Santis MC, et al. Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treat Rev. 2022;109:102434. doi:10.1016/j.ctrv.2022.102434

Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicentre pooled analysis of 5161 patients. The Lancet Oncology, 2022;23(1):149-160. doi:10.1016/S1470-2045(21)00589-1

Salas M, Mordin M, Castro C, et al. Health-related quality of life in women with breast cancer: A review of measures. BMC Cancer, 2022;22:246. doi:10.1186/s12885-021-09157-w

Loibl S, Azim HA Jr, Bachelot T, et al. ESMO expert consensus statements on the management of breast cancer during pregnancy (PrBC). Annals of Oncology, 2023;34(10):849-866. doi:10.1016/j.annonc.2023.08.001

Lambertini, M., Peccatori, F. A., Demeestere, I., Amant, F., Wyns, C., Stukenborg, J. B., ... & ESMO Guidelines Committee. (2020). Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Annals of oncology, 31(12), 1664-1678.

Abdel-Razeq H, Abu Rous F, Abuhijla F, Abdel-Razeq N, Edaily S. Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects. Clin Interv Aging. 2022;17:1445-1460. Published 2022 Sep 28. doi:10.2147/CIA.S365497

Zheng G, Leone JP. Male breast cancer: An updated review of epidemiology, clinicopathology, and treatment. Journal of Oncology, 2022;2022:7070483. doi:10.1155/2022/7070483

Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., ... & Zakalik, D. (2020). Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline. Journal of clinical oncology, 38(18), 2080-2106.

Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., ... & Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Jama, 304(9), 967-975.

Tarantino P, Morganti S, Curigliano G. Biologic therapy for advanced breast cancer: Recent advances and future directions. Expert Opinion on Biological Therapy, 2020;20(9):1009-1024. doi:10.1080/14712598.2020.1752176